Citigroup Maintains Neutral on Quest Diagnostics, Lowers Price Target to $130
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Patrick Donnelly maintains a Neutral rating on Quest Diagnostics (NYSE:DGX) and lowers the price target from $142 to $130.
October 25, 2023 | 11:02 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Citigroup has maintained a Neutral rating on Quest Diagnostics and lowered the price target from $142 to $130.
The news directly pertains to Quest Diagnostics (DGX) as Citigroup has maintained a Neutral rating on the company and lowered the price target. This could potentially impact investor sentiment and the stock's price in the short term, although the Neutral rating suggests that the overall outlook for the company remains stable.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100